OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Treatment Patterns for Calcitonin Gene-Related Peptide Monoclonal Antibodies Including Galcanezumab versus Conventional Preventive Treatments for Migraine: A Retrospective US Claims Study
Oralee J. Varnado, Janna Manjelievskaia, Wenyu Ye, et al.
Patient Preference and Adherence (2022) Vol. Volume 16, pp. 821-839
Open Access | Times Cited: 26
Oralee J. Varnado, Janna Manjelievskaia, Wenyu Ye, et al.
Patient Preference and Adherence (2022) Vol. Volume 16, pp. 821-839
Open Access | Times Cited: 26
Showing 1-25 of 26 citing articles:
Monoclonal Antibodies against Calcitonin Gene-Related Peptide for Migraine Prophylaxis: A Systematic Review of Real-World Data
Antun R. Pavelić, Christian Wöber, Franz Riederer, et al.
Cells (2022) Vol. 12, Iss. 1, pp. 143-143
Open Access | Times Cited: 37
Antun R. Pavelić, Christian Wöber, Franz Riederer, et al.
Cells (2022) Vol. 12, Iss. 1, pp. 143-143
Open Access | Times Cited: 37
Remote electrical neuromodulation for migraine prevention: A double‐blind, randomized, placebo‐controlled clinical trial
Stewart J. Tepper, Liron Rabany, Robert P. Cowan, et al.
Headache The Journal of Head and Face Pain (2023) Vol. 63, Iss. 3, pp. 377-389
Open Access | Times Cited: 18
Stewart J. Tepper, Liron Rabany, Robert P. Cowan, et al.
Headache The Journal of Head and Face Pain (2023) Vol. 63, Iss. 3, pp. 377-389
Open Access | Times Cited: 18
One-Year Compliance After Calcitonin Gene-Related Peptide Monoclonal Antibody Therapy for Migraine Patients in a Real-World Setting: A Multicenter Cross-Sectional Study
Mi‐Kyoung Kang, Jong‐Hee Sohn, Myoung-Jin Cha, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 3, pp. 734-734
Open Access
Mi‐Kyoung Kang, Jong‐Hee Sohn, Myoung-Jin Cha, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 3, pp. 734-734
Open Access
Treatment Patterns and Healthcare Resource Utilization by Gender and Migraine Frequency in Adult Patients Receiving Galcanezumab Versus Standard of Care Preventive Medications Over 24 months: A United States Retrospective Claims Study
Oralee J. Varnado, Michelle Vu, Erin Buysman, et al.
Patient Preference and Adherence (2025) Vol. Volume 19, pp. 543-567
Open Access
Oralee J. Varnado, Michelle Vu, Erin Buysman, et al.
Patient Preference and Adherence (2025) Vol. Volume 19, pp. 543-567
Open Access
Monthly Headaches and Severity in Patients on Galcanezumab or Traditional Preventive Migraine Medication: A 24-Month Claims and Electronic Health Records Study
Oralee J. Varnado, Michelle Vu, Gilwan Kim, et al.
Neurology and Therapy (2025)
Open Access
Oralee J. Varnado, Michelle Vu, Gilwan Kim, et al.
Neurology and Therapy (2025)
Open Access
Towards precision medicine in migraine: Recent therapeutic advances and potential biomarkers to understand heterogeneity and treatment response
Gabriella Juhász, Kinga Gecse, Dániel Baksa
Pharmacology & Therapeutics (2023) Vol. 250, pp. 108523-108523
Open Access | Times Cited: 10
Gabriella Juhász, Kinga Gecse, Dániel Baksa
Pharmacology & Therapeutics (2023) Vol. 250, pp. 108523-108523
Open Access | Times Cited: 10
Migraine and the Gender Divide
Aimen Vanood, India Rangel, Amaal J. Starling
Neurologic Clinics (2023) Vol. 41, Iss. 2, pp. 231-247
Closed Access | Times Cited: 9
Aimen Vanood, India Rangel, Amaal J. Starling
Neurologic Clinics (2023) Vol. 41, Iss. 2, pp. 231-247
Closed Access | Times Cited: 9
Treatment patterns of galcanezumab versus standard of care preventive migraine medications over 24 months: a US retrospective claims study
Oralee J. Varnado, Michelle Vu, Erin Buysman, et al.
Current Medical Research and Opinion (2024) Vol. 40, Iss. 4, pp. 635-646
Open Access | Times Cited: 3
Oralee J. Varnado, Michelle Vu, Erin Buysman, et al.
Current Medical Research and Opinion (2024) Vol. 40, Iss. 4, pp. 635-646
Open Access | Times Cited: 3
Persistence, effectiveness, and tolerability of anti‐calcitonin gene–related peptide monoclonal antibodies in patients with chronic migraine
Anna de Dios, Neus Pagès‐Puigdemont, Sergio R. Ojeda, et al.
Headache The Journal of Head and Face Pain (2024) Vol. 65, Iss. 1, pp. 24-34
Closed Access | Times Cited: 3
Anna de Dios, Neus Pagès‐Puigdemont, Sergio R. Ojeda, et al.
Headache The Journal of Head and Face Pain (2024) Vol. 65, Iss. 1, pp. 24-34
Closed Access | Times Cited: 3
Calcitonin Gene-Related Peptide Monoclonal Antibodies: Key Lessons from Real-World Evidence
Bianca Orlando, Gabriella Egeo, Cinzia Aurilia, et al.
Brain Sciences (2024) Vol. 14, Iss. 9, pp. 948-948
Open Access | Times Cited: 3
Bianca Orlando, Gabriella Egeo, Cinzia Aurilia, et al.
Brain Sciences (2024) Vol. 14, Iss. 9, pp. 948-948
Open Access | Times Cited: 3
Comparison of Treatment Patterns in Patients with Migraine Initiating Calcitonin Gene-Related Peptide Monoclonal Antibodies: A Retrospective Real-World US Study
Oralee J. Varnado, Brenna L. Brady, Anthony J. Zagar, et al.
Patient Preference and Adherence (2024) Vol. Volume 18, pp. 69-88
Open Access | Times Cited: 2
Oralee J. Varnado, Brenna L. Brady, Anthony J. Zagar, et al.
Patient Preference and Adherence (2024) Vol. Volume 18, pp. 69-88
Open Access | Times Cited: 2
Real-world Impact of Fremanezumab on Migraine-Related Health Care Resource Utilization in Patients with Comorbidities, Acute Medication Overuse, and/or Unsatisfactory Prior Migraine Preventive Response
Dawn C. Buse, Lynda J. Krasenbaum, Michael J. Seminerio, et al.
Pain and Therapy (2024) Vol. 13, Iss. 3, pp. 511-532
Open Access | Times Cited: 2
Dawn C. Buse, Lynda J. Krasenbaum, Michael J. Seminerio, et al.
Pain and Therapy (2024) Vol. 13, Iss. 3, pp. 511-532
Open Access | Times Cited: 2
Utilization, Expenditure, and Treatment Patterns Associated With Calcitonin Gene-Related Peptide Monoclonal Antibodies Reimbursed Subject to a Managed Access Protocol in Ireland
Amelia Smith, Karen Finnigan, Sarah Clarke, et al.
Value in Health (2024) Vol. 27, Iss. 8, pp. 1039-1045
Open Access | Times Cited: 2
Amelia Smith, Karen Finnigan, Sarah Clarke, et al.
Value in Health (2024) Vol. 27, Iss. 8, pp. 1039-1045
Open Access | Times Cited: 2
Cgrp Monoclonal Antibodies: Key Lessons from Real World Evidence
Bianca Orlando, Gabriella Egeo, Cinzia Aurilia, et al.
(2024)
Open Access | Times Cited: 2
Bianca Orlando, Gabriella Egeo, Cinzia Aurilia, et al.
(2024)
Open Access | Times Cited: 2
Monoclonal Antibodies Against Calcitonin Gene-related Peptide for Migraine Prophylaxis: A Systematic Review of Real-world Data
Antun R. Pavelić, Christian Wöber, Franz Riederer, et al.
(2022)
Open Access | Times Cited: 9
Antun R. Pavelić, Christian Wöber, Franz Riederer, et al.
(2022)
Open Access | Times Cited: 9
Emerging experimental drugs in clinical trials for migraine: observations and key talking points
William David Wells-Gatnik, Tiffany Y. Wences Chirino, Fatma Nur Onan, et al.
Expert Opinion on Investigational Drugs (2023) Vol. 32, Iss. 8, pp. 761-771
Closed Access | Times Cited: 5
William David Wells-Gatnik, Tiffany Y. Wences Chirino, Fatma Nur Onan, et al.
Expert Opinion on Investigational Drugs (2023) Vol. 32, Iss. 8, pp. 761-771
Closed Access | Times Cited: 5
Observational Retrospective Study in Patients Treated with Galcanezumab as Preventive Treatment for Migraine: The ORYGAM Study
Samuel Díaz Insa, Ángel Luis Guerrero Peral, J. Viguera Romero, et al.
Pain and Therapy (2024) Vol. 13, Iss. 3, pp. 557-576
Open Access | Times Cited: 1
Samuel Díaz Insa, Ángel Luis Guerrero Peral, J. Viguera Romero, et al.
Pain and Therapy (2024) Vol. 13, Iss. 3, pp. 557-576
Open Access | Times Cited: 1
Health care resource utilization and direct costs incurred over 24 months after initiating galcanezumab or standard-of-care preventive migraine treatments in the United States
Oralee J. Varnado, Michelle Vu, Erin Buysman, et al.
Journal of Managed Care & Specialty Pharmacy (2024) Vol. 30, Iss. 8, pp. 792-804
Open Access | Times Cited: 1
Oralee J. Varnado, Michelle Vu, Erin Buysman, et al.
Journal of Managed Care & Specialty Pharmacy (2024) Vol. 30, Iss. 8, pp. 792-804
Open Access | Times Cited: 1
Changes in use of acute and preventive medications for migraine after erenumab initiation over 12 months: A United States retrospective cohort study
Jasjit K. Multani, Robert Urman, Andrew S. Park, et al.
Headache The Journal of Head and Face Pain (2024) Vol. 65, Iss. 1, pp. 68-79
Open Access | Times Cited: 1
Jasjit K. Multani, Robert Urman, Andrew S. Park, et al.
Headache The Journal of Head and Face Pain (2024) Vol. 65, Iss. 1, pp. 68-79
Open Access | Times Cited: 1
Patient-reported outcomes related to migraine burden among patients treated with standard-of-care preventive medications or calcitonin gene-related monoclonal antibodies: a United States and Europe cross-sectional survey
Oralee J. Varnado, James Jackson, Lucas Scharf, et al.
Current Medical Research and Opinion (2024), pp. 1-12
Closed Access | Times Cited: 1
Oralee J. Varnado, James Jackson, Lucas Scharf, et al.
Current Medical Research and Opinion (2024), pp. 1-12
Closed Access | Times Cited: 1
Calcitonin Gene-Related Peptide (CGRP)-Targeted Treatments—New Therapeutic Technologies for Migraine
Linda Sangalli, Stefania Brazzoli
Future Pharmacology (2023) Vol. 3, Iss. 1, pp. 117-131
Open Access | Times Cited: 3
Linda Sangalli, Stefania Brazzoli
Future Pharmacology (2023) Vol. 3, Iss. 1, pp. 117-131
Open Access | Times Cited: 3
Treatment patterns for patients initiating novel acute migraine specific medications (nAMSMs) in the context of monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway
Zifan Zhou, Robert Urman, Karminder Gill, et al.
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 2
Zifan Zhou, Robert Urman, Karminder Gill, et al.
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 2
Algorithmus zur medikamentösen Migräneprophylaxe
Axel Heinze, Katja Heinze‐Kuhn, Carl Göbel, et al.
Schmerzmedizin (2024) Vol. 40, Iss. 3, pp. 32-37
Closed Access
Axel Heinze, Katja Heinze‐Kuhn, Carl Göbel, et al.
Schmerzmedizin (2024) Vol. 40, Iss. 3, pp. 32-37
Closed Access
Changes in Use of Migraine Medications, Healthcare Resource Utilization, and Associated Direct Costs Over 12 Months Following Initiation of Erenumab: A US Retrospective Real-World Analysis
Robert Urman, Nicole Princic, Fiston Vuvu, et al.
Pain and Therapy (2024) Vol. 13, Iss. 5, pp. 1299-1313
Open Access
Robert Urman, Nicole Princic, Fiston Vuvu, et al.
Pain and Therapy (2024) Vol. 13, Iss. 5, pp. 1299-1313
Open Access
Healthcare Utilization, Costs, and Treatment Discontinuation in Adults with Episodic Migraine Initiating Galcanezumab Versus Rimegepant: A US Retrospective Claims Analysis
Gilwan Kim, Margaret Hoyt, Armen Zakharyan, et al.
Advances in Therapy (2024) Vol. 42, Iss. 2, pp. 918-934
Open Access
Gilwan Kim, Margaret Hoyt, Armen Zakharyan, et al.
Advances in Therapy (2024) Vol. 42, Iss. 2, pp. 918-934
Open Access
